Molence· @MolenceBio · X·· 17 天前AI 评分56
AI 导读
Molence Bio 使用 Mol-1 的早期检查点搭建内部 de novo VHH 设计平台,并在自有湿实验中对 17 个多样化靶点完成测试,靶点级初始命中率介于 6% 至 63%。设计以 VHH-Fc 融合形式测试,靶点覆盖可溶性蛋白、受体胞外域和 GPCR,包括 BCMA、4-1BB、TNFR2、IL-4Rα、CCR8、CXCR4、CXCR6 和 CCR5。该平台把分子预测与经过实验测试的抗体设计衔接起来。
正文 · 原文
3/15 🧪 Binding hits across all 17 diverse targets, tested in our own wet lab.
Using an earlier checkpoint of Mol-1, we built an in-house de novo VHH design platform. Designs were tested as VHH-Fc fusions.
Initial target-level hit rates ranged from 6% to 63%, spanning soluble proteins, receptor extracellular domains and GPCRs—including BCMA, 4-1BB, TNFR2, IL-4Rα, CCR8, CXCR4, CXCR6 and CCR5.
The platform connects molecular prediction to experimentally tested antibody design.
#ProteinDesign
来源:Molence · x.com